GSK (LON:GSK) Announces Earnings Results

Key Points

• GSK exceeded third-quarter expectations, reporting earnings of 54.60p per share and revenue of approximately £8.89 billion, driven by specialty medicines and newer product launches.
• The company reaffirmed its 2026 outlook, although a £328 million restructuring charge reduced reported profit and management did not raise guidance after the earnings beat.
• GSK is expanding its oncology pipeline, planning to nearly double cancer medicines in clinical trials next year; recent positive trial results could support long-term growth, but the programs carry significant investment and development risk.

GSK (LON:GSK - Get Free Report) posted its earnings results on Wednesday. The company reported GBX 54.60 EPS for the quarter, Digital Look Earnings reports. The business had revenue of GBX 888.70 billion for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%.

GSK Price Performance

Shares of GSK traded down GBX 72.50 during mid-day trading on Wednesday, hitting GBX 1,851. 52,013,336 shares of the stock were exchanged, compared to its average volume of 12,515,744. The firm has a 50-day moving average of GBX 1,850.33 and a two-hundred day moving average of GBX 1,949.81. The company has a debt-to-equity ratio of 103.36, a quick ratio of 0.73 and a current ratio of 0.82. The company has a market cap of £74.17 billion, a PE ratio of 15.71, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. GSK has a 52-week low of GBX 1,664 and a 52-week high of GBX 2,282.

Trending Headlines about GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK reported third-quarter earnings of 54.60p per share and revenue of approximately £8.89 billion, topping expectations. Growth in specialty medicines and recently launched products supported the performance. GSK tops third-quarter estimates as new medicines drive growth, keeps outlook
• Positive Sentiment: The company reaffirmed its 2026 financial outlook, suggesting management remains confident in underlying operating momentum despite ongoing cost pressures. GSK delivers Q3 earnings beat, reaffirms 2026 outlook
• Positive Sentiment: GSK plans to nearly double the number of cancer medicines in clinical trials next year. The expansion could improve the company’s long-term oncology growth prospects, although the programs will require substantial investment and carry development risk. GSK to nearly double cancer drugs in trials, WSJ reports
• Positive Sentiment: Pipeline news also provided support: GSK’s rectal-cancer drug met its Phase 2 primary objective, while a bone-cancer treatment developed with Hansoh delayed disease progression in a late-stage Chinese study. GSK’s Rectal Cancer Drug Meets Primary Objective in Phase 2 Trial
• Neutral Sentiment: An executive disclosed an acquisition of GSK American depositary shares, a signal of insider confidence but a transaction unlikely to materially affect valuation. GSK Reports October Executive Notional ADS Acquisition on NYSE
• Negative Sentiment: A £328 million restructuring charge reduced reported profit. Investors may also be disappointed that GSK maintained, rather than raised, its outlook following the earnings beat. GSK keeps guidance as specialty drugs power sales, but restructuring charge dents profit

Insider Buying and Selling at GSK

In related news, insider Jonathan Symonds bought 1,500 shares of the company's stock in a transaction on Friday, September 18th. The shares were acquired at an average price of GBX 1,881 per share, with a total value of £28,215. Also, insider Anne Beal acquired 637 shares of GSK stock in a transaction that occurred on Friday, September 18th. The shares were purchased at an average price of GBX 4,985 per share, with a total value of £31,754.45. In the last three months, insiders bought 2,151 shares of company stock worth $6,021,921. Insiders own 0.20% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on GSK. Jefferies Financial Group restated a "buy" rating and set a GBX 2,500 price target on shares of GSK in a research report on Tuesday, October 20th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a GBX 2,000 price objective on shares of GSK in a research note on Tuesday, September 29th. Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a GBX 1,975 price target on shares of GSK in a report on Tuesday, September 8th. Finally, Berenberg Bank increased their price objective on GSK from GBX 2,000 to GBX 2,200 and gave the company a "hold" rating in a research report on Tuesday, September 15th. Two equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of GBX 2,064.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.